The Brave New World of Skin Grafting – From Foreskins to Foot Ulcers


By: Melissa Sattley

Dermagraft, a human skin replacement for the treatment of diabetic foot ulcers has been recommended to the FDA for approval on the condition that Advanced Tissue Sciences, Inc. and its partner Smith & Nephew plc perform a post marketing study.

Dermagraft is a living skin replacement produced from foreskin tissue removed at circumcisions which is then cultured in a laboratory. Dermagraft is then frozen for storage and shipped to physicians to be administered to patients.

In the U.S., it is estimated that diabetic foot ulcers affect nearly 15 percent of the 16 million patients with diabetes. The vote to recommend approval by the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee to the U.S. FDA was made after the company presented clinical data demonstrating that diabetic foot ulcers could be completely healed within 12 weeks with the use of Dermagraft.

Advanced Tissue Sciences, Inc. based in La Jolla, Calif., and Smith & Nephew plc are pursuing the worldwide commercialization of Dermagraft through a fifty-fifty joint venture.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.